KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Divestments (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Divestments for 17 consecutive years, with $279.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Divestments fell 16.22% to $279.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 billion, a 2.55% decrease, with the full-year FY2025 number at $1.1 billion, down 2.55% from a year prior.
  • Divestments was $279.0 million for Q4 2025 at Bristol Myers Squibb, roughly flat from $279.0 million in the prior quarter.
  • In the past five years, Divestments ranged from a high of $490.0 million in Q4 2022 to a low of $178.0 million in Q4 2021.
  • A 5-year average of $256.6 million and a median of $242.0 million in 2023 define the central range for Divestments.
  • Peak YoY movement for Divestments: soared 175.28% in 2022, then tumbled 50.82% in 2023.
  • Bristol Myers Squibb's Divestments stood at $178.0 million in 2021, then soared by 175.28% to $490.0 million in 2022, then crashed by 50.82% to $241.0 million in 2023, then surged by 38.17% to $333.0 million in 2024, then decreased by 16.22% to $279.0 million in 2025.
  • Per Business Quant, the three most recent readings for BMY's Divestments are $279.0 million (Q4 2025), $279.0 million (Q3 2025), and $270.0 million (Q2 2025).